Dapagliflozin plus calorie restriction for remission of type 2 diabetes: multicentre, double blind, randomised, placebo controlled trial.

ABSTRACT:

Objective

To assess the effect of dapagliflozin plus calorie restriction on remission of type 2 diabetes.

Design

Multicentre, double blind, randomised, placebo controlled trial.

Setting

16 centres in mainland China from 12 June 2020 to 31 January 2023.

Participants

328 patients with type 2 diabetes aged 20-70 years, with body mass index >25 and diabetes duration of <6 years.

Interventions

Calorie restriction with dapagliflozin 10 mg/day or placebo.

Main outcome measures

Primary outcome: incidence of diabetes remission (defined as glycated haemoglobin <6.5% and fasting plasma glucose <126 mg/dL in the absence of all antidiabetic drugs for at least 2 months); secondary outcomes: changes in body weight, waist circumference, body fat, blood pressure,

SUBMITTER: Liu Y 

PROVIDER: S-EPMC11752448 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature